Efficacy of Derinat as a Treatment for Murine and Androgenetic Alopecia Patients

    Chia‐Hung Wu, Wei-Chiao Chen, Chia-Hsun Hsieh, Yun‐Fang Liang, Weiju Li, Heqing Shen, Wei-Yen Wei, Ting-Yu Chou, Yen-Chun Chiu, Hao Huang, Wen‐Li Hsu
    Image
    Studysummary In this study, researchers found that Derinat, a TRPCs inhibitor, reduced oxidative stress and prolonged the anagen phase of hair growth in mice, supporting its potential as a therapy for androgenetic alopecia by improving clinical outcomes and enhancing quality of life for those affected.
    Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
    The study investigated the efficacy of Derinat, a TRPCs inhibitor, in treating Androgenetic alopecia (AGA), a common type of hair loss. The research found that Derinat extended the lifespan of Caenorhabditis elegans worms by restraining oxidative stress-induced aging. In mice, Derinat maintained the hair cycle at the anagen phase by reducing TRPCs-mediated reactive oxygen species (ROS) accumulation. Bioinformatics analysis confirmed AGA pathogenesis is associated with TRPCs-regulated oxidative stress and inflammation. In clinical trials involving AGA patients aged 20 to 75, Derinat treatment improved the outcomes of oral medication, increasing hair density and diameter after 4 and 8 weeks of use, and mitigated the impairment of their quality of life. The study concluded that Derinat has potential anti-oxidative stress efficacy that extends hair growth patterns and maintains the hair cycle at the anagen phase.
    Discuss this study in the Community →

    Research cited in this study

    19 / 19 results